CoChat

Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about 70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM. We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (α-AL-HPLN) to specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated thatα-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin formulation. In this way,α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2012/126906

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ALCAM/CD166 is highly expressed in osteosarcoma cell lines. Western immunoblot analysis of osteosarcoma cell lines probed with α-ALCAM antisera. There is high total cell expression of ALCAM in HOS, KHOS, KHOS240s, and SJSA with moderate expression in the MNNG-HOS cell line. A pancreatic cancer cell line, HPAF, with known high levels of ALCAM expression was used as a positive control. MiaPaCa, a pancreatic cancer cell line with known lack of ALCAM expression served as a negative control. Membrane-localized ALCAM isoform is present at 105 kDa. β-Actin was used as an internal loading control.
Figure 1 ALCAM/CD166 is highly expressed in osteosarcoma cell lines. Western immunoblot analysis of osteosarcoma cell lines probed with α-ALCAM antisera. There is high total cell expression of ALCAM in HOS, KHOS, KHOS240s, and SJSA with moderate expression in the MNNG-HOS cell line. A pancreatic cancer cell line, HPAF, with known high levels of ALCAM expression was used as a positive control. MiaPaCa, a pancreatic cancer cell line with known lack of ALCAM expression served as a negative control. Membrane-localized ALCAM isoform is present at 105 kDa. β-Actin was used as an internal loading control.CC BY · PubMed Central
Figure 2 Surface ALCAM expression in osteosarcoma cell lines. Fluorescent immunohistochemistry showing membranous ALCAM expression in osteosarcoma cell lines in comparison to a known ALCAM expressing pancreatic cancer cell line, HPAF (positive control), and ALCAM negative cell line, MiaPaCa. ALCAM binding shown in red (Alexa Fluor 564) and nuclei counterstained with DAPI (20x magnification).
Figure 2 Surface ALCAM expression in osteosarcoma cell lines. Fluorescent immunohistochemistry showing membranous ALCAM expression in osteosarcoma cell lines in comparison to a known ALCAM expressing pancreatic cancer cell line, HPAF (positive control), and ALCAM negative cell line, MiaPaCa. ALCAM binding shown in red (Alexa Fluor 564) and nuclei counterstained with DAPI (20x magnification).CC BY · PubMed Central
Figure 3 ALCAM expression in human osteosarcoma patient tumor samples. Immunohistochemistry studies in human paraffin-embedded localized and pulmonary metastatic osteosarcoma samples show mild to strong expression of ALCAM (brown) both membranous and cytoplasmic in appearance in comparison to normal human muscle and human lung. Tissues were counterstained with hematoxylin (magnification 20x).
Figure 3 ALCAM expression in human osteosarcoma patient tumor samples. Immunohistochemistry studies in human paraffin-embedded localized and pulmonary metastatic osteosarcoma samples show mild to strong expression of ALCAM (brown) both membranous and cytoplasmic in appearance in comparison to normal human muscle and human lung. Tissues were counterstained with hematoxylin (magnification 20x).CC BY · PubMed Central
Figure 4 α-ALCAM-targeted PLNs bind specifically to osteosarcoma cell lines. α-ALCAM cys-diabody conjugated PLNs show specific binding (red) to two osteosarcoma cell lines expressing ALCAM, KHOS240s and MNNG-HOS. There was no binding to a cell line that does not express ALCAM, MiaPaCa. Fluorescence microscopy of PLNs is shown in red and DAPI nuclear counterstaining in blue (magnification 20x).
Figure 4 α-ALCAM-targeted PLNs bind specifically to osteosarcoma cell lines. α-ALCAM cys-diabody conjugated PLNs show specific binding (red) to two osteosarcoma cell lines expressing ALCAM, KHOS240s and MNNG-HOS. There was no binding to a cell line that does not express ALCAM, MiaPaCa. Fluorescence microscopy of PLNs is shown in red and DAPI nuclear counterstaining in blue (magnification 20x).CC BY · PubMed Central
Figure 5 α-ALCAM-conjugated PLNs show cell-specific targeting in a time-dependent manner. α-ALCAM-conjugated PLNs were incubated with osteosarcoma cells for 0, 1, 2, and 4 hours then washed off. α-ALCAM targeted PLNs bind specifically to the ALCAM expressing osteosarcoma cell line KHOS240s at one hour and reach a maximum binding at 4 hours of incubation. Fluorescence microscopy of PLNs (shown in red) with DAPI (blue) nuclear counterstaining (magnification 20x).
Figure 5 α-ALCAM-conjugated PLNs show cell-specific targeting in a time-dependent manner. α-ALCAM-conjugated PLNs were incubated with osteosarcoma cells for 0, 1, 2, and 4 hours then washed off. α-ALCAM targeted PLNs bind specifically to the ALCAM expressing osteosarcoma cell line KHOS240s at one hour and reach a maximum binding at 4 hours of incubation. Fluorescence microscopy of PLNs (shown in red) with DAPI (blue) nuclear counterstaining (magnification 20x).CC BY · PubMed Central
Figure 6 α-ALCAM-conjugated PLNs are internalized via receptor-mediated endocytosis. α-ALCAM-targeted PLNs incubated with the osteosarcoma cell line KHOS240s at 4 degrees and at 37 degrees Celsius show inhibition of receptor-mediated endocytosis at 4°C and rapid internalization of targeted PLNs at 37°C versus untargeted PLNs that do not bind under either circumstance. Fluorescence microscopy of PLNs (shown in red) with DAPI (blue) nuclear counterstaining (magnification 20x).
Figure 6 α-ALCAM-conjugated PLNs are internalized via receptor-mediated endocytosis. α-ALCAM-targeted PLNs incubated with the osteosarcoma cell line KHOS240s at 4 degrees and at 37 degrees Celsius show inhibition of receptor-mediated endocytosis at 4°C and rapid internalization of targeted PLNs at 37°C versus untargeted PLNs that do not bind under either circumstance. Fluorescence microscopy of PLNs (shown in red) with DAPI (blue) nuclear counterstaining (magnification 20x).CC BY · PubMed Central
Figure 7 Containment of doxorubicin over time in drug-loaded liposomal vehicles. Containment studies of loaded HPLNs versus conventional PEG-liposomes showed that leakage increased significantly with time (P < 0.0001), with geometric means at 4 hours, 1 day, and 6 days being, respectively, 0.9%, 4.6%, and 3.1% for conventional doxorubicin-loaded PEG-liposomes and 1.2%, 3.2%, and 5.9% for HPLN. There were no significant differences between the vehicles or the effects of pH or temperature that could be detected at 4 hours or 1 day. However, at 6 days HPLN had 1.9-fold greater overall leakage than DOX (P < 0.001; 95% C.I. 1.6- to 2.4-fold). Lowering pH from 7.4 to 4.5 increased leakage by a factor of 1.5 (P = 0.01; 95% C.I. 1.1- to 2.1-fold) with enhanced leakage at 37 degrees compared to 4 degrees (P = 0.03).
Figure 7 Containment of doxorubicin over time in drug-loaded liposomal vehicles. Containment studies of loaded HPLNs versus conventional PEG-liposomes showed that leakage increased significantly with time (P < 0.0001), with geometric means at 4 hours, 1 day, and 6 days being, respectively, 0.9%, 4.6%, and 3.1% for conventional doxorubicin-loaded PEG-liposomes and 1.2%, 3.2%, and 5.9% for HPLN. There were no significant differences between the vehicles or the effects of pH or temperature that could be detected at 4 hours or 1 day. However, at 6 days HPLN had 1.9-fold greater overall leakage than DOX (P < 0.001; 95% C.I. 1.6- to 2.4-fold). Lowering pH from 7.4 to 4.5 increased leakage by a factor of 1.5 (P = 0.01; 95% C.I. 1.1- to 2.1-fold) with enhanced leakage at 37 degrees compared to 4 degrees (P = 0.03).CC BY · PubMed Central
Figure 8 Cytotoxicity IC50s for doxorubicin-loaded vehicles and free DOX. Targeted and untargeted hybrid PLNs were incubated with osteosarcoma cell lines in comparison to free doxorubicin and conventional PEG-liposomal doxorubicin. Mean log IC50 for osteosarcoma cell lines shows that untargeted hybrid PLNs have a 6-fold increase in cytotoxicity over conventional liposomal formulation. ALCAM targeted hybrid PLNs (HPLN) show an additional 2-fold increase over untargeted HPLNS and 12-fold increase in cytotoxicity over conventional PEG-liposomal doxorubicin. Geometric mean IC50s were derived from seven, five, and three sets of MTT assay experiments in, respectively, the KHOS240s, HOS, and MNNG-HOS cell lines. Error bars correspond to 1 standard error for mean log (IC50). Within each cell line, differences among vehicles are highly significant (P < 0.0001). Confidence intervals for pairwise ratios of IC50s, corrected for multiple comparisons, are summarized in Table 1.
Figure 8 Cytotoxicity IC50s for doxorubicin-loaded vehicles and free DOX. Targeted and untargeted hybrid PLNs were incubated with osteosarcoma cell lines in comparison to free doxorubicin and conventional PEG-liposomal doxorubicin. Mean log IC50 for osteosarcoma cell lines shows that untargeted hybrid PLNs have a 6-fold increase in cytotoxicity over conventional liposomal formulation. ALCAM targeted hybrid PLNs (HPLN) show an additional 2-fold increase over untargeted HPLNS and 12-fold increase in cytotoxicity over conventional PEG-liposomal doxorubicin. Geometric mean IC50s were derived from seven, five, and three sets of MTT assay experiments in, respectively, the KHOS240s, HOS, and MNNG-HOS cell lines. Error bars correspond to 1 standard error for mean log (IC50). Within each cell line, differences among vehicles are highly significant (P < 0.0001). Confidence intervals for pairwise ratios of IC50s, corrected for multiple comparisons, are summarized in Table 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Huvos AG Bone Tumors: Diagnosis, Treatment, and Prognosis 1991 Philadelphia, Pa, USA WB Saunders
  2. Gurney JG Swensen AR Bulterys M Malignant bone tumors Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995 1999 Bethesda, Md, USA SEER program, National Cancer Institute 99 110

Cited by

See all 50

Metadata

Authors
Federman, N., Chan, J., Nagy, J. O., Landaw, E. M., McCabe, K., Wu, A. M., Triche, T., Kang, H., Liu, B., Marks, J. D., & Denny, C. T.
Affiliations
  • Mattel Children's Hospital (US)
  • NanoValent Pharmaceuticals Inc., Bozeman, MT 59718-4012, USA
  • University of California, Los Angeles (US)
  • University of Southern California (US)
  • Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
  • University of California, San Francisco (US)
Corresponding author
Federman, Noah
Venue
Sarcoma
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-11
ISSN
  • 1357-714X (ISSN-L)
  • 1369-1643
OpenAlex
W4213018315
Cited by
44
References
30
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 5
FWCI
0.91
Type
journal article
Language
en
Open access
Locations
  • Sarcoma (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
  • National Science Foundation (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
osteosarcoma, ALCAM, ALDH1, cell surface receptors, liposomal doxorubicin, targeted drug delivery, immunoconjugates, cytotoxicity, tumor growth inhibition, bone cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.